证券代码：603207 证券简称：小方制药 公告编号：2025-020 为进一步推动公司业务的发展，公司拟提请股东大会依照《中华人民共和国 公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司证券发行注册管理办法》等法律法规、规范性文件及《公司章 程》等有关规定，授权董事会在不影响公司主营业务及保证公司财务安全的前提 下，择机办理向特定对象发行融资总额不超过人民币3亿元且不超过最近一年末 净资产20%的股票事宜，授权期限为本次授权相关议案经公司2024年年度股东大 会审议通过之日起至2025年年度股东大会召开之日止。 二、本次授权事宜具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会根据相关法律、法规、规范性文件及《公司章程》等规定，对公 司实际情况及相关事项进行自查论证，确认公司是否符合以简易程序向特定对象 发行股票的条件。 上海小方制药股份有限公司 关于提请股东大会授权董事会全权办理以简易程序 向特定对象发行股票相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性 ...

上海小方制药股份有限公司 2024 年度募集资金存放与实际使用情况专项报告及鉴证报告 普华永道 对募集资金存放与实际使用情况专项报告的鉴证报告 普华永道中天特审字(2025)第 0115 号 (第一页,共三页) 上海小方制药股份有限公司董事会: 我们接受委托,对上海小方制药股份有限公司(以下简称"小方制药")关于 2024 年度的募集资金存放与实际使用情况专项报告(以下简称"募集资金存放与实 际使用情况专项报告")执行了合理保证的鉴证业务。 小方制药管理层的责任是按照中国证券监督管理委员会公告[2022]15 号《上市 公司监管指引第 2 号-上市公司募集资金管理和使用的监管要求(2022 年修订)》、 上海证券交易所颁布的《上海证券交易所上市公司自律监管指引第 1 号 -- 规范运 作(2023年12月修订)》及《上海证券交易所上市公司自律监管指南第1号 公告格 式(2025年4月修订)-第十三号 上市公司募集资金相关公告》编制募集资金存放与 实际使用情况专项报告。这种责任包括设计、执行和维护与募集资金存放与实际使 用情况专项报告编制相关的内部控制,保证募集资金存放与实际使用情况专项报告 的真实、准确和完整 ...

关于上海小方制药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 委托单位：上海小方制药股份有限公司 审计单位：普华永道中天会计师事务所(特殊普通合伙) 联系电话： 上海小方制药股份有限公司 2024 年度控股股东及其他关联方占用资金情况专项报告 怎可能用手机,"扫一扫",永速入"在哪个干燥机器中比重右是否出具有效全件可用全社伴手表的利用。 【我们都不快,"扫",我选入"在哪会计师行必须"当窗手在"Danpv/Markgacca",【日常公司】字3572周上。 普华永道 关于上海小方制药股份有限公司 控股股东及其他关联方占用资金情况专项报告 書华永道中天特审字(2025)第 0116号 (第一页,共二页) 上海小方制药股份有限公司董事会: 2、 附表 我们审计了上海小方制药股份有限公司(以下简称"小方制药")2024年 12月 31 日的合并及公司资产负债表、2024年度合并及公司利润表、合并及公司股东权 益变动表、合并及公司现金流量表和财务报表附注(以下合称"财务报表"),并于 2025年 4月 28 日出具了报告号为普华永道中天审字(2025)第 10 ...

国信证券股份有限公司关于 上海小方制药股份有限公司 2024 年度 募集资金存放与使用情况的专项核查意见 国信证券股份有限公司（以下简称"保荐机构"）作为上海小方制药股份有 限公司（以下简称"小方制药"或"公司"）首次公开发行股票并上市的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所上 市公司自律监管指引第 11 号——持续督导》等有关规定，对小方制药 2024 年度 募集资金存放与使用情况进行了审慎核查，具体核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 根据中国证券监督管理委员会于 2023 年 9 月 13 日签发的证监发行字 [2023]2147 号文《关于同意上海小方制药股份有限公司首次公开发行股票注册的 批复》，公司于 2024 年 8 月向境内投资者发行人民币普通股 40,000,000 股，每股 发行价格为人民币 12.47 元，募集资金总额为 498,800,000.00 元。扣除发行 ...

国信证券股份有限公司关于 2024 年度持续督导年度报告书 | 保荐机构名称：国信证券股份有限公司 | 被保荐公司名称：上海小方制药股份有限公司 | | | | --- | --- | --- | --- | | 保荐代表人姓名：陈振瑜 | 联系方式：021-60933183 联系地址：上海市浦东新区民生路 | | | | | 1199 弄证大五道 | | | | | 口广场 1 15 | 号楼 | 楼 | | 保荐代表人姓名：刘雅昕 | 联系方式：021-60933130 | | | | | 联系地址：上海市浦东新区民生路 1199 弄证大五道 | | | | | 口广场 1 15 | 号楼 | 楼 | 根据《证券法》《证券发行上市保荐业务管理办法》《上海证券交易所股票上 市规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等 有关法律、法规的规定，国信证券股份有限公司（以下简称"国信证券"或"保 荐机构"）作为上海小方制药股份有限公司（以下简称"小方制药"、"公司"或 "发行人"）首次公开发行股票并上市的保荐机构，对小方制药进行持续督导。 现就 2024 年度持续督导工作总结如下： | ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 129,071,756.14, representing a 3.33% increase compared to CNY 124,911,943.02 in the same period last year[3] - Net profit attributable to shareholders was CNY 59,842,662.17, reflecting a 14.63% increase from CNY 52,202,813.76 year-over-year[3] - Total operating revenue for Q1 2025 was CNY 129,071,756.14, an increase of 1.85% compared to CNY 124,911,943.02 in Q1 2024[18] - Net profit for Q1 2025 was CNY 59,842,662.17, up 14.93% from CNY 52,202,813.76 in Q1 2024[19] - Basic and diluted earnings per share decreased by 15.91% to CNY 0.37, compared to CNY 0.44 in the same period last year[3] - Earnings per share (EPS) for Q1 2025 was CNY 0.37, down from CNY 0.44 in Q1 2024[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 4.00% to CNY 53,217,171.28, down from CNY 55,435,440.02 in the previous year[3] - Cash flow from operating activities for Q1 2025 was CNY 53,217,171.28, a decrease from CNY 55,435,440.02 in Q1 2024[23] - Cash inflow from investment activities was CNY 65,441,013.89, significantly higher than CNY 3,000,000.00 in Q1 2024[24] - Cash flow from financing activities generated a net inflow of CNY 3,721,723.19 compared to a net outflow of CNY 1,755,469.56 in Q1 2024[24] - The net increase in cash and cash equivalents for the period is 94,329,440.61, compared to 45,190,347.54 in the previous period[25] - The beginning balance of cash and cash equivalents is 282,535,421.74, remaining unchanged from the previous period[25] - The ending balance of cash and cash equivalents is 376,864,862.35, an increase from 327,725,769.28 in the previous period[25] Assets and Liabilities - Total assets increased by 2.26% to CNY 1,434,081,842.95, up from CNY 1,402,448,475.00 at the end of the previous year[4] - As of March 31, 2025, the company's total assets amounted to RMB 1,434,081,842.95, an increase from RMB 1,402,448,475.00 as of December 31, 2024, reflecting a growth of approximately 2.3%[12] - The company's current assets totaled RMB 1,062,599,399.00, compared to RMB 1,031,934,369.91 at the end of 2024, indicating an increase of about 2.9%[14] - The company's total liabilities decreased to RMB 139,910,551.94 from RMB 168,213,793.02, a reduction of approximately 16.8%[15] - The total equity increased to RMB 160,559,967.00 from RMB 160,000,000.00, reflecting a growth of about 0.35%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,072[8] - The largest shareholder, Yunjia Far East Co., Ltd., holds 58.80% of the shares, totaling 94,080,000 shares[8] - Shareholders' equity attributable to shareholders rose by 4.86% to CNY 1,294,171,291.01, compared to CNY 1,234,234,681.98 at the end of the previous year[4] Operational Insights - The company received government subsidies amounting to CNY 80,944.59, which are closely related to its normal business operations[5] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[10] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported[10] Cost Management - Total operating costs decreased to CNY 59,389,758.13 from CNY 64,012,373.77, representing a reduction of 7.88%[18] - Research and development expenses for Q1 2025 were CNY 2,270,871.64, down from CNY 3,845,805.32 in Q1 2024, indicating a 40.83% reduction[18] - The company reported a financial expense of CNY -1,777,303.27, which is an increase in costs compared to CNY -951,684.20 in the previous year[19] Inventory and Receivables - Accounts receivable rose to RMB 94,314,926.51 from RMB 87,850,912.95, marking an increase of around 7.3%[12] - Inventory decreased slightly to RMB 43,655,134.17 from RMB 45,205,028.30, a decline of approximately 3.4%[14] - The company reported a significant reduction in other payables from RMB 123,181,401.33 to RMB 94,577,217.84, a decrease of about 23.2%[15]

Financial Performance - The company's operating revenue for 2024 reached ¥474,583,693.35, a slight increase of 0.57% compared to ¥471,871,615.15 in 2023[22] - The net profit attributable to shareholders for 2024 was ¥205,271,095.50, reflecting a growth of 0.81% from ¥203,627,027.66 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥205,253,741.46, which is a 3.05% increase from ¥199,187,012.27 in 2023[22] - Cash flow from operating activities amounted to ¥212,208,147.68, up by 5.97% from ¥200,258,125.51 in the prior year[22] - The total assets of the company at the end of 2024 were ¥1,402,448,475.00, a significant increase of 96.79% from ¥712,650,946.12 in 2023[22] - The net assets attributable to shareholders increased to ¥1,234,234,681.98, representing a growth of 112.82% compared to ¥579,954,207.64 at the end of 2023[22] - The basic earnings per share for 2024 were ¥1.53, a decrease of 10.00% from ¥1.70 in 2023[23] - The diluted earnings per share also stood at ¥1.53, reflecting the same 10.00% decline compared to the previous year[23] Dividend Policy - The company plans to distribute a cash dividend of ¥15.00 per 10 shares, totaling approximately ¥240,839,950.50, which accounts for 117.33% of the net profit attributable to shareholders for 2024[5] - The cash dividend amount for the reporting period is 240,839,950.50 RMB, which represents 117.33% of the net profit attributable to ordinary shareholders[151] - The company has a cash dividend policy that prioritizes cash distributions, aiming for at least 50% of the distributable profit to be paid out in cash if there are no major investment plans[147] Market and Product Development - The company is focusing on enhancing brand construction and expanding its multi-channel layout, including strengthening offline sales channels and developing online marketing strategies[32] - The company has established a B2C e-commerce flagship store and partnered with instant retail platforms to diversify its marketing channels[32] - The company aims to enhance consumer education on medication through new media and training for retail chains[32] - The company is focused on developing a product pipeline for home-use external medications, with an emphasis on both generic and innovative products[104] - The company is currently developing several new products, including mupirocin ointment for skin infections and lidocaine cream for local anesthesia[86] Research and Development - The company invested a total of 15.1054 million yuan in R&D during the reporting period, resulting in 2 invention patents and 20 utility model patents granted[33] - Research and development expenses amounted to 15,105.42 million RMB, a decrease of 7.22% from the previous year[54] - The R&D investment amounted to RMB 417.37 million, representing 12.11% of revenue, which is significantly higher compared to peers[90] - Major R&D projects included Polyvinyl Alcohol Eye Drops with an investment of 1.55 million RMB (0.33% of operating revenue), and Oxytetracycline Ear Drops with 0.48 million RMB (0.10% of operating revenue), both showing a 100% increase compared to the previous year[92] Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[8] - The company is committed to optimizing management systems and strengthening risk control to ensure steady business development[31] - The company faces market competition risks, particularly in its external-use drug products, which may impact market share and financial performance if competitors introduce more effective or cost-efficient products[107] - Regulatory changes in the pharmaceutical industry could pose risks, especially if new policies affect pricing or procurement processes, potentially leading to decreased sales and profitability[108] Environmental Compliance - The company has established environmental protection mechanisms and is actively monitoring its emissions[160] - The company has not reported any exceedances of pollutant discharge standards during the monitoring period[162] - The company is committed to maintaining compliance with environmental regulations and improving its sustainability practices[161] - The company faced an administrative penalty in May 2024 for exceeding permitted pollutant discharge concentrations, resulting in a fine of RMB 200,000[172] Governance and Management - The company has established a robust governance structure, holding 8 board meetings, 7 supervisory meetings, and 3 shareholder meetings during the reporting period to ensure effective decision-making[116] - The company has not reported any major discrepancies in governance practices compared to regulatory requirements, indicating compliance and effective management[116] - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 8.565 million yuan[128] - The company has maintained a stable management team with no changes in shareholding[119] Shareholder Commitments - The controlling shareholder, Hong Kong YunJia, has committed to a share lock-up period of 36 months from the date of the company's stock listing, during which no transfer or management of shares will occur[180] - The commitments include a stipulation that any share reduction must be announced 3 trading days in advance[181] - The company will adhere to the latest regulatory rules regarding share lock-up or reduction if there are changes in regulations[182] - The company commits to publicly explaining any failure to fulfill shareholding commitments and will compensate for any losses incurred by investors[186]

上海小方制药股份有限公司董事会 关于独立董事独立性情况的专项意见 2025年4月28日 根据中国证监会《上市公司独立董事管理办法》、上海证券交易 所《股票上市规则》、《上市公司自律监管指引第 1 号—规范运作》等 有关规定，上海小方制药股份有限公司（以下简称"公司 "）董事 会就公司在任独立董事卓福民先生、杨力先生、余玮女士的独立性情 况进行评估并出具如下专项意见： 经核查独立董事卓福民先生、杨力先生、余玮女士的任职经历以 及签署的相关自查文件，上述人员及其直系亲属、主要社会关系均未 在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司 独立董事管理办法》、《上海证券交易所上市公司自律监管指引第 1 号 --规范运作》中对独立董事独立性的相关要求。 上海小方制药股份有限公司董事会 ...

本人作为上海小方制药股份有限公司（以下简称"公司"）的 独立董事， 严格遵照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》(以下简称"《证券法》")、《上市公司独立董事管理办法》《上市公司治 理准则》《上海证券交易所股票上市规则》等法律法规以及《公司章程》《独立董事 工作制度》等有关规定，忠实履行独立董事职责，积极出席公司历次董事会、股 东大会和董事会专门委员会，认真审议各项议案，对重要事项发表独立意见，运 用自身专业知识，为公司经营发展提供意见与建议，切实维护公司及全体股东合 法权益。现就本人2024年度履职情况报告如下： 一、 独立董事基本情况 本人卓福民,1951年出生，经济学硕士，高级经济师，特级管理会计师。 1987年1月至1995年5月任上海市经济体制改革办公室宏观处、企业处处长、主任 助理，1995年5月至2002年6月，任上海实业控股有限公司（香港）副董事长、 CEO,2002年7月至2005年12月，任祥峰中国投资公司董事长兼CEO,2006年1月至 2013年12月任上海科星创业投资有限公司创始人兼董事长，2008年1月至2016年 12月任纪源资本管理合伙 ...